At 01:35 on July 27, 2019, Beijing time, Immuron Ltd (Imrn.us) shares changed, and the stock price rose rapidly by 7.81%. As of press release, the stock reported $3.45 per share, with a trading volume of 129.5 million shares, a turnover rate of 0.32%, and an increase of 6.56%.

According to the latest 2018-12-31 interim report data, the stock achieved operating income of 708526.00 US dollars, net profit of -1.15 million US dollars, earnings per share of -0.34 US dollars, gross profit of 538951.22 US dollars, and a price-earnings ratio of -6.08 times.

In terms of institutional ratings, there are currently no institutions that have made suggestions to “buy, hold, or sell” this stock.

In the biotechnology industry, where Immuron Ltd's stock is located, the overall decline was 0.08%. Among its related individual stocks,Love Kline, Acasti Pharma Inc., and Ocular Therapeutix Inc increased significantly. Neuralstem Inc, Sellas Life Sciences Group Inc, and Xenetic Biosciences Inc were relatively active. The turnover rates were 66.08%, 36.15%, and 21.49% respectively. Related individual stocks with large amplitudes were Aikline, Neurotrope Inc, and Cortexyme Inc. The amplitudes were 29.06%, 24.20%, and 23.97%, respectively.

Immuron Ltd Company Profile: Immuron is a biopharmaceutical company developing polyclonal antibodies for the treatment and prevention of diseases. Its products include Travelan, IMM-124E for treating NASH, and IMM-529 for C. difficile infections.

(The above content is completed by Money Call, an intelligent machine writer for optional stocks. It is only used as a reference for users to watch the market, and is not used as a basis for trading.)